ArticleScience immunology2021
Early cross-coronavirus reactive signatures of humoral immunity against COVID-19.
Abstract read
In one paragraph
Article in Science immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study.Scientific reports · 2024Trial
- HKU1 immune imprinting is associated with post-COVID symptoms after SARS-CoV-2 infection.iScience · 2026Article
- CoronaVac-induced antibodies that facilitate Fc-mediated neutrophil phagocytosis track with COVID-19 disease resolution.Emerging microbes & infections · 2025Article
- SARS-CoV-2 antibody responses in children exhibit higher FcR engagement and avidity than in adults.Nature communications · 2025Article
- Minimal Impact of Prior Common Cold Coronavirus Exposure on Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination or Infection Risk in Older Adults in Congregate Care.Open forum infectious diseases · 2025Article
- Review
- Post-transfusion activation of coagulation pathways during severe COVID-19 correlates with COVID-19 convalescent plasma antibody profiles.The Journal of clinical investigation · 2025Article
- Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models.Journal of virology · 2025Article
- Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA.Nature biomedical engineering · 2025Article
- Mathematical modelling of the heterogeneity of disease progression and treatment outcomes in patients with COVID-19.Frontiers in microbiology · 2025Article
- Reduced seasonal coronavirus incidence in high-risk population groups during the COVID-19 pandemic.Immunity, inflammation and disease · 2024Article
- Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge.Nature communications · 2024Article
- Immune imprinting and next-generation coronavirus vaccines.Nature microbiology · 2023Review
- Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases.Science translational medicine · 2023Article
- Article
- Plasmablasts in previously immunologically naïve COVID-19 patients express markers indicating mucosal homing and secrete antibodies cross-reacting with SARS-CoV-2 variants and other beta-coronaviruses.Clinical and experimental immunology · 2023Article
- Inside-out assembly of viral antigens for the enhanced vaccination.Signal transduction and targeted therapy · 2023Article
- Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines.Cell reports. Medicine · 2023Article
- Review
- Evidence for Aerosol Transfer of SARS-CoV-2-Specific Humoral Immunity.ImmunoHorizons · 2023Article
Corrections and comments
- Update of
Authors and funding
42 authors.
Paulina KaplonekRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Chuangqi WangDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-4779-2231
Yannic BartschRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0002-3844-3056
Stephanie FischingerRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0003-2307-3379
Matthew J GormanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Kathryn BowmanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0003-4222-5286
Jaewon KangRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Diana DayalSpace Exploration Technologies Corporation, Hawthorne, CA, USA.ORCID 0000-0003-3313-0007
Patrick MartinSpace Exploration Technologies Corporation, Hawthorne, CA, USA.
Radoslaw P NowakDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0605-0071
Alexandra-Chloé VillaniBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID 0000-0001-7461-0408
Ching-Lin HsiehDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-3665-5717
Nicole C CharlandDepartment of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-8895-8701
Anna L K GonyeBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID 0000-0003-0034-1756
Irena GushterovaBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID 0000-0002-8405-6348
Hargun K KhannaDepartment of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-0932-7187
Thomas J LaSalleBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID 0000-0002-8390-6072
Kendall M Lavin-ParsonsDepartment of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.
Brendan M LilleyDepartment of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-0735-4130
Carl L LodensteinDepartment of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.
Kasidet ManakongtreecheepBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Justin D MargolinDepartment of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-5544-7318
Brenna N McKaigDepartment of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-9913-2262
Maricarmen Rojas-LopezDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Brian C RussoDepartment of Medicine, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6433-5617
Nihaarika SharmaBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Jessica TantivitBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Molly F ThomasBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID 0000-0002-1393-6559
Moshe Sade-FeldmanBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID 0000-0002-0022-0287
Jared FeldmanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0002-4387-9954
Boris JulgRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0002-4687-9626
Eric J NillesBrigham and Women's Hospital, Boston, MA, USA.
Elon R MuskSpace Exploration Technologies Corporation, Hawthorne, CA, USA.
Anil S MenonSpace Exploration Technologies Corporation, Hawthorne, CA, USA.
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-7337-6306
Jason S McLellanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0003-3991-542X
Aaron SchmidtRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0003-3627-2553
Marcia B GoldbergBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID 0000-0003-4266-9733
Michael R FilbinBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID 0000-0002-2588-7504
Nir HacohenBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.ORCID 0000-0002-2349-2656
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-0050-989X
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7680-9215
Funding
COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6MTechnology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Bryan Briney · 2018 to 2026
$32.0MMultidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8MDemystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8MSingle-cell genomic profiling to identify immune signatures of bacterial sepsis in humansR01AI153142 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI FILBIN, MICHAEL, GOLDBERG, MARCIA B · 2021 to 2025
$5.0MImmunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7MSARS-CoV-2 Variant TestingR01AI146785 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2020 to 2024
$3.3MCHLAMYDIA PNEUMONIAE AND MACROPHAGES IN ATHEROSCLEROSISR01AI042790 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI BYRNE, GERALD IRWIN · 1999 to 2003
$983kNCI NIH HHS U01 CA260476NIAID NIH HHS 75N93019C00052NIAID NIH HHS R01 AI042790NIAID NIH HHS R01 AI146785NIAID NIH HHS R01 AI153142NIAID NIH HHS R37 AI080289NIAID NIH HHS T32 AI007387NIAID NIH HHS U19 AI135995
Abstract
The introduction of vaccines has inspired hope in the battle against SARS-CoV-2. However, the emergence of viral variants, in the absence of potent antivirals, has left the world struggling with the uncertain nature of this disease. Antibodies currently represent the strongest correlate of immunity against SARS-CoV-2, thus we profiled the earliest humoral signatures in a large cohort of acutely ill (survivors and nonsurvivors) and mild or asymptomatic individuals with COVID-19. Although a SARS-CoV-2–specific immune response evolved rapidly in survivors of COVID-19, nonsurvivors exhibited blunted and delayed humoral immune evolution, particularly with respect to S2-specific antibodies. Given the conservation of S2 across β-coronaviruses, we found that the early development of SARS-CoV-2–specific immunity occurred in tandem with preexisting common β-coronavirus OC43 humoral immunity in survivors, which was also selectively expanded in individuals that develop a paucisymptomatic infection. These data point to the importance of cross-coronavirus immunity as a correlate of protection against COVID-19.
Indexed as
Cross ReactionsImmunity, HumoralAdolescentCohort StudiesCoronavirus OC43, HumanCOVID-19Disease ProgressionHumansImmunoglobulin Class SwitchingReceptors, FcSARS-CoV-2Spike Glycoprotein, CoronavirusSurvivorsYoung AdultReceptors, FcSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.